Immune System News and Research

RSS

NUVO announces positive results from WF10 Phase 2 clinical trial for severe allergic rhinitis

Nuvo Research Inc. a specialty pharmaceutical company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies and on the development of its immune modulating drug candidate WF10, today announced that its European Phase 2 clinical trial evaluating WF10 as a treatment for severe allergic rhinitis met its primary endpoint.

8 Nov 2010

Thirteen myths about arthritis and rheumatic disease

A diagnosis of arthritis or another rheumatic disease can cause someone to feel anxious and even a little overwhelmed. Being a knowledgeable and empowered patient can help alleviate some of those feelings, and being able to navigate through the many misconceptions about arthritis and rheumatic diseases is vitally important.

8 Nov 2010

Research on immune system may help develop improved vaccines for cancer

Researchers at the University of Cambridge hope to revolutionise cancer therapy after discovering one of the reasons why many previous attempts to harness the immune system to treat cancerous tumours have failed.

8 Nov 2010

Scientists identify genes that enable some immune systems to halt HIV; finding could spur drug, vaccine development

Tiny variants in a protein that alerts the body to infection could explain how one in 300 HIV-infected people are able to resist the onset of AIDS for years without needing any treatment, researchers said Thursday in a study published online in the journal Science, Agence France-Presse reports

8 Nov 2010

Hydroxychloroquine may reduce cardiac neonatal lupus in subsequent pregnancies: Research

Women with anti-SSA/Ro antibodies and a previous child who has heart block a condition where the electrical signal that makes the heart beat is damaged may potentially decrease their risk of delivering another child with life threatening heart disease by taking hydroxychloroquine (Plaquenil), according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

Inviragen to present data on CHIKV vaccine at ASTMH meeting

Inviragen, a biotechnology company developing vaccines to protect against infectious diseases worldwide, together with investigators at the University of Texas Medical Branch (UTMB) and the Division of Vector Borne Diseases (DVBD) of the Centers for Disease Control and Prevention, will make an oral presentation today at the annual American Society of Tropical Medicine and Hygiene (ASTMH) meeting on preclinical results of the Company's experimental chikungunya virus (CHIKV) vaccine.

8 Nov 2010

Researchers take first step towards understanding of rare skin cancer

Leeds-based scientists, funded by Yorkshire Cancer Research headquartered in Harrogate, North Yorkshire, plan to introduce the genetic material of a virus into normal human skin cells to produce skin cells that have features of Merkel Cell Carcinoma cancers.

8 Nov 2010

InNexus receives $116,760 cash grant under QTDP program to develop DXL anti-cancer antibodies

InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.

8 Nov 2010

Skin to blood transformation in the lab

In a new study scientists have successfully transformed human skin cells into blood without first being sent through a primordial, stem-cell-like state. The findings were published online in the journal Nature. Earlier work has shown that fibroblast cells from mouse skin, treated with the right cocktail of chemicals, can be transformed into neurons and heart muscle. This is a first with human cells.

7 Nov 2010

Tuberculosis on the rise in the UK

According to health authorities, tuberculosis (TB) – a severe lung infection that has killed millions in the past, is resurfacing again in the UK. Last year the number of cases reached more than 9,000, the highest number for nearly 30 years. The numbers were revealed by the Health Protection Agency in its annual report on tuberculosis this Thursday.

5 Nov 2010

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results and operational highlights for the quarter ended September 30, 2010.

4 Nov 2010

NWBT receives $490,000 in two grants under QTDP program

Northwest Biotherapeutics today announced that the company has received approximately $490,000 in two grants under the Qualified Therapeutic Discovery Project Grants Program. The maximum award was received for both grants.

4 Nov 2010

Combination of DC-CIK and stem cell therapy effective to prevent cancer recurrence after surgery

"For brain cancer patients after surgery, the combined DC-CIK and stem cell therapy from Cellonis Biotechnologies can be a very effective method in preventing cancer recurrence," says renowned cancer doctor Dr. Dinggang Li.

4 Nov 2010

Modified sugar compound protects against world's deadliest viruses

When a team of European researchers sought to discover how a class of antiviral drugs worked, they looked in an unlikely place: the sugar dish. A new research report appearing in the Journal of Leukocyte Biology suggests that a purified and modified form of a simple sugar chain may stop fast-acting and deadly viruses, such as Ebola, Lassa, or Marburg viruses, in their tracks.

4 Nov 2010

New antibody with SGN-35 drug produces remission in Hodgkin lymphoma

An antibody loaded with an anti-cancer agent produced complete or partial remissions in 38 percent of patients with relapsed or therapy-resistant Hodgkin lymphoma enrolled in a phase I clinical trial, investigators report in the Nov. 4 issue of the New England Journal of Medicine.

4 Nov 2010

Study links positive well-being to higher telomerase activity

Positive psychological changes that occur during meditation training are associated with greater telomerase activity, according to researchers at the University of California, Davis, and the University of California, San Francisco. The study is the first to link positive well-being to higher telomerase, an enzyme important for the long-term health of cells in the body.

4 Nov 2010

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2010, and company highlights.

4 Nov 2010

Bortezomib reduces inflammation and promotes bone healing in arthritis models

A new study by Greek researchers suggests that the biologic drug bortezomib (Velcade), a proteasome inhibitor used to treat multiple myeloma (bone marrow cancer), may represent a promising treatment for rheumatoid arthritis (RA). In this study, bortezomib displayed favorable effects in an animal model of inflammatory arthritis that mimics RA, in reducing disease severity and inflammation, and promoting bone healing. Full findings of this study are published in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

3 Nov 2010

Top 10 Medical Innovations for 2011

From pill-sized cameras to radioactive compounds that let doctors "see" inside a patient's brain, Cleveland Clinic's Top 10 Medical Innovations for 2011 showcases new techniques, therapies and approaches to treating a host of diseases.

3 Nov 2010

APS summit focuses on Antiphospholipid Syndrome research

Antiphospholipid Syndrome (APS) is a condition that may be responsible for up to one-third of strokes in people under age 50, up to one-fifth of all cases of blood clots in large veins, and one-quarter of recurrent miscarriages. Nonetheless, relatively few randomized clinical trials have been conducted involving people with APS, and those completed have included small numbers of participants.

3 Nov 2010